Composition of and method for treating injury and/or skin conditions
US-2024139138-A1 · May 2, 2024 · US
Use of peptide for alleviating pain
US9623077B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9623077-B2 |
| Application number | US-201514723914-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 28, 2015 |
| Priority date | May 28, 2015 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method for alleviating pain in a subject in need thereof, which comprises administering an effective amount of piscidin (PCD) peptide and a pharmaceutically acceptable carrier to the subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for alleviating neuropathic pain in a subject in need thereof, wherein the method comprises administering an effective amount of piscidin (PCD) peptide and a pharmaceutically acceptable carrier to the subject, wherein the PCD peptide is a PCD-1 peptide comprising the amino acid sequence of SEQ ID NO: 1. 2. The method of claim 1 , wherein the neuropathic pain is caused by a neuroinflammation. 3. The method of claim 2 , wherein the PCD-1 peptide inhibits the neuroinflammation. 4. The method of claim 1 , wherein the subject is a human. 5. The method of claim 1 , wherein the PCD-1 peptide inhibits expression level of COX-2. 6. The method of claim 1 , wherein the PCD-1 peptide inhibits expression level of iNOS. 7. The method of claim 1 , wherein the PCD-1 peptide decreases activation of microglias. 8. The method of claim 1 , wherein the PCD-1 peptide decreases activation of astrocytes. 9. The method of claim 1 , wherein the PCD-1 peptide decreases expression level of IL-1β. 10. The method of claim 1 , wherein the PCD-1 peptide decreases expression level of phospho-mTOR. 11. The method of claim 1 , wherein the PCD-1 peptide increases expression level of TGF-β1. 12. The method of claim 1 , wherein the effective amount is in a range of from about 1 μg to about 50 μg. 13. The method of claim 1 , wherein the effective amount is in a range of from about 10 μg to about 30 μg.
Assignees
Inventors
Classifications
- A61K38/1706Primary
from fish · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9623077B2 cover?
- The present invention relates to a method for alleviating pain in a subject in need thereof, which comprises administering an effective amount of piscidin (PCD) peptide and a pharmaceutically acceptable carrier to the subject.
- Who is the assignee on this patent?
- Academia Sinica, Nat Sun Yat-Sen Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1706. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).